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 Abstract 
 Background: Although advance care planning and the completion of advance directives 
(ADs) are important tools to avoid unwanted aggressive care once patients have lost their 
decision-making capacity, only a minority of cancer patients are admitted with completed 
ADs, and little is known about patients’ wishes regarding AD consultations.  Methods: For 1 
year, every new patient admitted to the hematology/oncology outpatient clinic of the Univer-
sity Hospital Regensburg received a self-administered questionnaire comprising a self-eval-
uation of AD knowledge and questions about preferences regarding consultation partners 
and the time of consultation. Disease-related data were collected from medical records. Sta-
tistics were calculated with SPSS.  Results: Of the 500 questionnaires handed out, 394 (75%) 
were evaluable and analyzed. Twenty-eight percent of the participants had completed an AD 
(living will or health care proxy). Ninety-two percent of the participants without ADs had nev-
er received a consultation offer from any professional involved. Only 20% perceived a clear 
relation between cancer and AD consultations. More than 50% of the participants without ADs 
were in favor of consultations ‘now’ or ‘in a few weeks’, while more than 40% objected to AD 
consultations.  Conclusions: Oncology patients have a large unmet demand for AD consulta-
tions. However, a relevant percentage of these patients object to AD consultations. Structured 
and early AD consultation offers should be made, and early discussions about indications for 
aggressive treatment should take place.  © 2014 S. Karger AG, Basel 
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 Introduction 
 Respect for a patient’s autonomy is considered a fundamental ethical principle, leading 
to the concepts of shared decision-making and informed consent. In the case of impaired 
consciousness, particularly in end-of-life situations, patient autonomy is also the ethical basis 
for the legal instruments of advance care planning. In Germany – as in the USA – there are 
three types of formal expression of a patient’s autonomy  [1] .
 The living will is meant to inform the attending physician about the patient’s decisions 
regarding an end-of-life situation and thereby defines the guidelines for the following 
treatment such as analgesics, antibiotics, artificial respiration, parenteral nutrition, and 
cardiopulmonary resuscitation. In addition, the documentation of a health care proxy can be 
used to designate another person to decide in more complex health care situations. The health 
care proxy fully represents the will of the patient in case of impaired consciousness regarding 
health care issues, so that an additional living will is not required but recommended. 
Furthermore, the durable power of attorney aims at private and financial concerns in inca-
pacitating medical conditions by appointing a person of trust to take care of specific domains. 
In Germany and many other Western countries, these three elements of advance directives 
(ADs) are legally binding on medical staff if written down properly and signed by the patient.
 In 2009, the revision of a statute concerning ADs in Germany led to a broad public 
discussion about living wills and resulted in a strict statute strengthening patients’ autonomy. 
Independent of an underlying disease, a written living will is now legally binding with regard 
to medical decisions if a patient is no longer able to make decisions himself due to illness or 
incapacity  [2] .
 Preceding surveys showed that 20–40% of cancer patients report on having a completed 
AD (living will and/or durable power of attorney for health care) and that this rate has 
remained constant over many years  [3–6] . It seems to be even lower than 20% in different 
European countries independent of the detailed legal situation  [7–12] . In cancer patients, 
early AD consultations are of particular importance due to the imminent risk of impaired 
consciousness in advanced cases  [13–20] . Recent studies showed that ADs improve the 
process of dying by reducing the patient’s fear, the stress on relatives  [21] , and the physician’s 
risk of burnout  [22] . In addition, they might have a positive impact on costs incurred on the 
health system as well as the patient  [23] . These factors lead to the question of how to underline 
the importance of ADs in the public’s perception so that their acceptance will be improved 
among patients.
 It has been shown that, paradoxically, hospitalized cancer patients prefer AD consulta-
tions with any admitting physician to an AD consultation with their oncologist  [24] . A recent 
investigation challenged this conclusion and showed that cancer patients would prefer their 
oncologist if he made ‘the first step’ toward initiating an AD discussion  [4] . These surveys only 
included hospitalized cancer patients. Hospitalization due to worsening health, complica-
tions, or planned intensive therapies marks an ideal time point in the disease course for initi-
ating AD discussions. Thus far, there have been no comparable surveys in an outpatient 
setting. Furthermore, little is known about cancer patients’ preference  [25] regarding when 
to address advance care planning issues.
 This survey was initiated to investigate cancer patients’ knowledge about the legal instru-
ments of advance care planning, the patients’ preferences regarding AD consultation partners, 
and the preferred time point for AD consultation after the first diagnosis.
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 Patients and Methods 
 Design 
 For a period of 1 year, a self-administered questionnaire (online questionnaire 1; for all online suppl. 
material, see www.karger.com/doi/10.1159/000363508) was handed out to every patient admitted to the 
hematology/oncology outpatient clinic of the University Hospital Regensburg, excluding patients admitted 
with coagulation disorders that were not the subject of our survey. The study was approved by the institu-
tional ethics committee.
 Patients 
 Between August 2009 and July 2010, 500 questionnaires were handed out to 525 consecutive first-time 
admissions to the hematology/oncology outpatient clinic, and 394 questionnaires (75%) were returned and 
could be analyzed. The patients’ characteristics are summarized in  table 1 .
 Data Collection 
 We designed a questionnaire comprising a self-evaluation of the patients’ knowledge about ADs and 
questions about their consultation partner in case they had prearranged ADs, about which consultation 
partner they favored, and about the favored AD consultation time in relation to the time of the survey as well 
as in relation to the disease status. Furthermore, a consultation was offered to patients without an AD.
 From the medical records of all participants, demographic data and data related to the disease (particu-
larly the time since diagnosis) were collected. Depending on the diagnosis, concomitant diseases, and their 
general health condition, we separated the patients into five prognosis groups as outlined in the Results 
section below.
 Statistical Analysis 
 Statistics were performed with SPSS. For the statistical dependence between completed ADs and age, 
disease duration, and estimated prognosis, Spearman’s rank correlation coefficients were calculated.
Participants Nonparticipants
Total number 394 131
Age, years
Range 17 – 86 19 – 90
Mean 57.5 59.3
Median 59.0 62.1
Standard deviation 15.3 15.1
Gender, n
Male 219 (55.6%) 72 (55.0%)
 Female 175 (44.4%) 59 (45.0%)
Disease, n
Hematologic neoplasia 198 (50.3%) 59 (45.0%)
Solid tumor 131 (33.2%) 46 (35.1%)
Nonmalignant 65 (16.5%) 24 (17.3%)
Missing 2 (1.5%)
Disease duration, months
Mean 32 29
Median 7 10
Standard deviation 54 42
Prognosis, n
Nonmalignant 65 (16.5%) 26 (21.0%)
Curative intention 117 (29.7%) 21 (16.9%)
Palliative >2 years 118 (29.9%) 33 (26.6%)
Palliative 0.5 – 2 years 52 (13.2%) 26 (21.0%)
Palliative <6 months 42 (10.7%) 18 (14.5%)
Missing 7
 Table 1.  Demographic and 
disease characteristics of the 
participants and nonparticipants
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 Results 
 Participants 
 The participants ( table 1 ) had a mean age of 58 years (range: 17–86), and 56% (219/394) 
were male. A total of 84% (329/394) had a malignant disease, of whom 60% (198/329) had 
a hematologic neoplasia and 40% (131/329) had a solid tumor. Patients with nonmalignant 
disease consulted our outpatient clinic for the examination of cytopenias or other suspected 
conditions in which no malignant disease could be found or they had a different hematologic 
nonmalignant disease.
 The prognosis groups were separated into the categories ‘no malignant disease’ and 
‘curative intention’, including patients with complete remission in follow-up care or patients 
with high-grade lymphoma or acute leukemia under therapy, as well as the ‘palliative’ 
category, which was further separated into the three subgroups ‘life expectancy >2 years’, ‘life 
expectancy between 6 months and 2 years’, and ‘life expectancy <6 months’ according to the 
underlying disease, the disease status, and the general health condition.
 Patients with indolent lymphoma or plasmacytoma or patients in good condition with 
solid tumors such as breast or prostate cancer were mostly classified into the ‘life expectancy 
>2 years’ subgroup. Most patients with metastatic solid tumors (e.g. lung, stomach, or colon 
cancer) were classified into the ‘between 6 months and 2 years’ subgroup. Patients in poor 
condition with extensive solid tumors or rapidly growing solid tumors, such as malignant 
melanoma or pancreatic cancer, or with high-grade hematologic malignancies without the 
option of life-prolonging therapy were classified into the ‘life expectancy <6 months’ sub-
group.
 Completed ADs and Knowledge about ADs 
 In all, 28% (109/394) of the participants had completed an AD (living will or health care 
proxy) at the time of our survey; 92% (251/272) of all the patients without ADs who answered 
this question had never received a consultation offer from a professional involved in their 
treatment.
 AD Consultation Preferences 
 Of the 285 participants without completed ADs, 231 (81%) specified their preferred 
AD consultation partner: 8% (19/231) wished to have legal advice, of whom 37% (7/19) 
0
Primary care physician
Hematologist/oncologist
Other physician
Attorney/solicitor
Social services
Others
Missing answers
10 20 30 40
Percentage
50 60 70
AD consultation only
More than 1 answer
 Fig. 1. Preferred AD consultation 
partners of the participants with-
out ADs. 
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wanted only legal advice and 63% (12/19) specified more than 1 preferred AD consultation 
partner; 26% (60/231) chose an AD consultation with their hematologist/oncologist [53% 
(32/60) exclusively; 47% (28/60) gave more than 1 answer], and 163 participants preferred 
an AD consultation with their primary care physician, meaning that 71% (163/231) of all 
the participants who specified a preferred AD consultation partner chose their primary 
care physician [82% (133/163) exclusively; 18% (30/163) gave more than 1 answer; 
 fig. 1 ].
 When asked about the preferred time for an AD consultation in relation to the disease 
status ( fig. 2 ), 47% (135/286) of the respondents commented that consultations about ADs 
should take place independently of a malignant disease. Another 33% (93/286) stated that 
an AD should only be issued when the patient asks for it; 12% (33/286) declared that an AD 
consultation should take place after the first cancer diagnosis, and another 9% (25/286) of 
the respondents wished to have an AD consultation in the case of incurable malignant disease. 
Even most of the patients within the worst prognosis subgroups with an estimated life expec-
tancy <2 years stated that AD consultations should take place independently of a malignant 
disease ( table 2 ).
 A total of 239 of the 285 participants without ADs (84%) responded to the question about 
the preferred time for an AD consultation in relation to the time of our survey (n = 259 due 
0LVVLQJ£DQVZHUV
$Q\WLPH£LQGHSHQGHQWO\
RI£D£PDOLJQDQW£GLVHDVH
2QO\£ZKHQ£WKH£SDWLHQW£DVNV
IRU£DQ£$'£FRQVXOWDWLRQ
2QO\£DIWHU£GLDJQRVLQJ£DQ
LQFXUDEOH£PDOLJQDQW£GLVHDVH
5LJKW£DIWHU£GLDJQRVLQJ
D£PDOLJQDQW£GLVHDVH
0 5 10 15 20
3HUFHQWDJH
25 3530 40
 Fig. 2. Preferred AD consultation 
in relation to the disease of the 
participants without completed 
ADs. 
 Table 2. Preferred AD consultation in relation to disease severity (number of participants)
 Prognosis Total
no m alignant 
disease
curative 
intention
palliative 
>2 years
palliative 
0.5 – 2 years
palliative 
<6 months
Independently of a malignant disease 14 35 25 14 11 99
Only when the patient asks for an AD consultation 15 23 23 3 7 71
Right after the first diagnosis of a malignant disease 9 7 7 3 1 27
Only after the diagnosis of an incurable malignant
disease 5 8 3 3 0 19
Total 43 73 58 23 19 216
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to multiple answers;  fig. 3 ); 5% (14/259) of the responses expressed that a consultation 
should have taken place already, 22% (56/259) stated that ‘now’ (at the time of the survey) 
was a good time for an AD consultation, and 26% (68/259) expressed that a participant 
wished to receive a consultation offer within the next few weeks. These answers were summa-
rized as participants willing to discuss AD issues in the near future. On the consent document, 
all participants received an offer for AD consultation with a physician. However, not a single 
patient made an appointment, even of the participants who answered ‘should have already 
taken place’, ‘now’, or ‘in a few weeks’.
3DOOLDWLYH££PRQWKV
3DOOLDWLYH£²£\HDUV
3DOOLDWLYH£!£\HDUV
&XUDWLYH£LQWHQWLRQ
1RQPDOLJQDQWGLVHDVH 6KRXOG£KDYH£WDNHQ
SODFH£DOUHDG\
1RZ£ZRXOG£EH£D
JRRGWLPH
5HSHDW$'£FRQVXOWDWLRQ
RIIHU£LQ£D£IHZ£ZHHNV
1RW£QRZ£EHFDXVH£$'£LV
FXUUHQWO\£QRW£DQ£LVVXHIRU£PH
1RW£QRZ£EHFDXVH£,£GRQRW
ZDQW£WR£JHWLQYROYHG£LQ£WKH£LVVXH
1R£$'£FRQVXOWDWLRQ£DWDOO
Q 
Q 
Q 
Q 
Q 
  
3HUFHQWDJH
  
 Fig. 3. Preferred AD consultation time in relation to the time of the survey of the participants without com-
pleted ADs. 
Nonmalignant disease
Curative intention
Palliative >2 years
Palliative 0.5–2 years
Palliative <6 months
0 10 20 30 40
Percentage
50 60 70 80 90 100
Against In favor
 Fig. 4. Preferences for AD consul-
tations in the near future of the 
participants without ADs. 
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 The answers ‘not now, because AD is currently not an issue for me’ [33% (79/239) of all 
the respondents without ADs], ‘not now, because I do not want to get involved in the issue’ 
[9% (22/239)], and ‘no AD consultation at all’ [8% (20/239)] were summarized as repre-
senting participants not willing to discuss AD issues at the time of the survey or in the near 
future. There was a larger proportion of these answers from patients with nonmalignant 
diseases [ fig. 4 ; 65% (32/49) of the respondents without AD], but even of the patients with 
malignant diseases, a large fraction [40% (35/87) in a curative and 44% (54/123) in a palli-
ative situation] postponed discussions about AD issues. However, a worsening prognosis 
resulted in an increased acceptance of AD discussions compared with the patients without 
malignant diseases or with the patients treated with curative intention ( fig. 4 ). But even of all 
the 85 patients (regardless of the current AD status) with a very limited prognosis of <2 years, 
18% (15/85) still postponed written commitments in the context of legal instruments of 
patient autonomy.
 Correlations 
 We found a significant correlation between the patients’ age and the proportion of 
completed ADs (Spearman’s ρ: 0.275; significance level: 0.01). Furthermore, a significant 
correlation between the time since diagnosis and the proportion of completed ADs (Spear-
man’s ρ: 0.185; significance level: 0.01) was observed. There was also a positive correlation 
between poor prognosis and the proportion of completed ADs; however, the prognosis did 
not seem to be an independent factor as there was a relation between prognosis and disease 
duration. Nevertheless, we could show an independent correlation between the patients’ 
prognosis and the preferred point of time for a consultation regarding AD issues (Spearman’s 
ρ: –0.186; significance level: 0.01).
 Discussion 
 In our survey, only 25% of the participants reported on having a completed living will, 
whereas 76% stated that they precisely know, and another 10% that they approximately 
know, the meaning and relevance of a living will. This high self-evaluated level of knowledge 
originates most likely from the public discussion about the revision of a statute concerning 
ADs in Germany in 2009. The patients seemed to overrate their knowledge, as the awareness 
180
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AD completion
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Legal advice
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 Fig. 5. Differences in the stated 
preferences regarding the consul-
tation partner between the par-
ticipants with and those without 
completed ADs. 
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of the possibility of assigning a health care proxy, which was not the focus of the public 
discussion, was much lower.
 As reported before  [24] , our results show as well that patients without ADs prefer a 
consultation with their primary care physician (71%) to a consultation with their oncologist 
(26%). Although the survey was conducted on patients visiting a university hospital outpa-
tient clinic for the first time, most of them had a cancer history of several months or years 
and had previously been treated by other oncologists, and still they preferred the primary 
care physician for discussing AD issues. Surprisingly, more than half of the patients with 
completed ADs had sought legal advice before ( fig. 5 ), whereas only few patients without 
completed ADs asked for legal consultation. This indicates that socioeconomic factors or 
personality traits such as safety needs might play a role in the patients’ preferences for AD 
consultation  [26] .
 Almost half of all the participants who answered this question (nearly equal to the 
number of participants without completed ADs) stated that AD consultations should take 
place independently of a cancer diagnosis. Only 20% of the patients directly linked their 
interest in AD consultation to the cancer diagnosis  [14] . The willingness to consider one’s 
personal transience seems to increase with age and longer disease duration  [27, 28] , but a 
cancer diagnosis alone does not generate an immediate readiness for end-of-life discussions 
and for the legal instruments of patient autonomy in the case of impaired consciousness  [5, 
29] .
 In our cohort, 28% of the participants without ADs stated that an AD consultation should 
already have taken place or should take place ‘now’ at the time of the survey. There obviously 
is a large unmet need for AD consultation. Repeated consultation offers seem to be appro-
priate to reach patients who are uncertain about a potentially negative impact of ADs on 
optimal cancer treatment or who have other fears  [30, 31] . Offering structured and repeated 
AD consultations to outpatients is more challenging than offering them to hospitalized 
patients as it requires an appropriate infrastructure and qualified and dedicated personnel. 
Furthermore, AD consulting often seems to be facilitated by a hospital admission as the 
reasons for hospitalization, such as upcoming intensive therapy, medical complications, or 
worsening health condition, can prompt AD discussions  [25, 32, 33] .
 As recently reported, many patients seem to expect the first step toward an AD consul-
tation from the physicians involved  [4] . Although our survey was performed in a hematology/
oncology department and included an AD consultation offer in the consent form, the majority 
of the patients still preferred AD consultations with their primary care physician, in contrast 
to recent findings  [4] . The primary care physician obviously remains the person of trust 
regarding therapeutic limitations. In the study performed by Dow et al.  [4] on inpatients, it 
was reported that 95% of the patients considered discussing AD issues at admission ‘very or 
somewhat important’. However, these data were acquired by a physician in an interview 
setting, which might have led to an overestimation of the patients’ readiness for discussing 
AD issues. In our survey, an anonymous invitation to an AD consultation was offered, requiring 
the active participation of the patient by making an appointment. Remarkably, none of the 
patients made an appointment, and almost half of the patients without ADs even objected to 
the AD consultation offer at the time of the survey (‘currently not an issue’, ‘do not want to 
get involved in the issue’, and ‘no AD consultation at all’) and did not wish to receive another 
consultation offer in a few weeks. This was independent of age, the disease duration, and the 
prognosis. However, in this study, a minority of 5% of the patients definitely seemed to 
dismiss AD consultations.
 As known from routine clinical practice, there seems to be a group of patients who are 
not willing to discuss therapeutic limitations or end-of-life matters or decide on treatment 
options in case of impaired consciousness  [1, 7–10, 34–37] . The legal instruments of patient 
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autonomy fail in these patients. There are no surveys investigating how or whether this group 
of patients can be reached for AD consultations, but it is very likely that even with optimized 
communication strategies, not all patients will accept the legal instruments of patient 
autonomy in the case of impaired consciousness. Thus, a fraction of cancer patients ignores 
the opportunity to define unwanted medical interventions after losing their decision-making 
capacity. Not discussing end-of-life matters is also an autonomous decision, but it imposes 
more responsibility on the physicians involved, as treatment decisions might be required 
without a statement of the patient about his/her preferences. In medical emergencies, this 
may easily lead to undesired treatment because maximum therapy is frequently initiated if 
no limitations have been determined in advance  [38] .
 In palliative care, precautions are usually arranged for threatening emergencies. As in the 
cancer patient population, these precautions can be communicated to some but not all palli-
ative care patients. In a small group of patients, the complete responsibility for decisions 
about medical interventions remains with the physicians involved, and decisions about 
potential interventions in case of emergencies are often made preemptively in team confer-
ences of palliative caretakers. With or without ADs, the medical indication remains the pivotal 
question and the physicians’ responsibility.
 Our survey has some limitations. We only investigated the patients’ point of view, omitting 
the physicians’ perspective in discussing AD issues. Although we reached a large represen-
tative sample, including a diversity of patients with hematologic and nonhematologic as well 
as malignant and nonmalignant diagnoses in a large urban academic primary care cancer 
center, not all patients answered all questions, and some questions were only answered by 
relatively small numbers of patients. Another limitation is the different legal situation in 
different countries. In Germany, the revision of a statute concerning ADs in 2009 caused a 
broad public discussion, which might have led not only to more acceptance and increased 
general knowledge but also to less acceptance and uncertainty due to the public dispute. 
However, results comparable to those of previous studies indicate that personality traits play 
a larger role than the detailed legal situation.
 Communication strategies for bringing up AD issues in cancer patients should reasonably 
include the family doctor as the patients’ preferred person of trust and the oncologist as the 
physician with expert knowledge about the natural course of the malignant disease. Further 
investigations of the group of patients not willing to use the legal instruments of patient 
autonomy are required. Strengthening the concept of a durable power of attorney for health 
care may be an option for patients who object to completing a written living will. With patients 
who also object to a durable power of attorney, an early consideration of medical indications 
for invasive treatment should take place. Particularly, an early discussion between cancer 
specialists and family doctors about medical indications in patients with advanced malignant 
disease and other limiting medical conditions seems necessary to avoid unwanted aggressive 
care  [39] .
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